… Colorectal cancer is the third most common cause of cancer … Among people diagnosed
with metastatic colorectal cancer, … The primary treatment for unresectable metastatic CRC is …

… , disease-free interval, maximum size of metastases, and WHO performance status, the
estimate of the association of treatment group for OS also showed a significant benefit in favor of …

… For example, patient characteristics including age; performance status; comorbid illness;
prior systemic therapy; tumor characteristics including resectability, location, and disease …

Background Metastatic colorectal cancer (mCRC) remains a lethal disease. Survival, however,
is increasing due to a growing number of treatment options. Yet due to the number of …

… Presurgical CRF stratification values are defined for lung 47 and colorectal cancer, 58
with less than 15 mL O 2 ⋅kg −1 ⋅min −1 associated with an elevated risk of complications, …

… Colorectal cancer is the second leading cause of cancer-related death worldwide. About
20% of patients suffer from metastatic disease at diagnosis, while about one-third of patients …

… During the past two decades, much progress has been made in the treatment of patients
with metastatic colorectal cancer (mCRC). More effective systemic therapy became available, …

… First, the NCR did not register data on comorbidity, performance status, and details of treatment
regimens during our study period, which may have differed between primary tumor sites, …

An increasing number of patients with metastatic colorectal cancer (mCRC) are able to
receive 3 or more lines of therapy. Treatments in this setting can include regorafenib (an oral …

… If a poor performance status is observed as a result of tumor aggressivity, a doublet ±
targeted therapy is indicated, if possible. When the deterioration results from patient frailty or …